Mutant FOXO1 Controls an Oncogenic Network via Enhancer Accessibility and RNA Polymerase Pause Release [ATAC-Seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 29 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Diffuse large B-cell lymphomaThis series is part of our curated briefing on it.
- Samples
- 29 samples: 29 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Mutant FOXO1 controls an oncogenic network via enhancer accessibilityCell genomics · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE243496_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1018666 and SRA study SRP461569. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 29 sample titles: 29 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7789518 ATACseq_NUDUL1_FOXO1_FKBP_0hA
- GSM7789519 ATACseq_NUDUL1_FOXO1_FKBP_0hB
- GSM7789520 ATACseq_NUDUL1_FOXO1_FKBP_0.25hA
- GSM7789521 ATACseq_NUDUL1_FOXO1_FKBP_0.25hB
- GSM7789522 ATACseq_NUDUL1_FOXO1_FKBP_0.5hA
- GSM7789523 ATACseq_NUDUL1_FOXO1_FKBP_0.5hB
- GSM7789524 ATACseq_NUDUL1_FOXO1_FKBP_1hA
- GSM7789525 ATACseq_NUDUL1_FOXO1_FKBP_1hB
- GSM7789526 ATACseq_NUDUL1_FOXO1_FKBP_2hA
- GSM7789527 ATACseq_NUDUL1_FOXO1_FKBP_2hB
- GSM7789528 ATACseq_OCILY1_FOXO1_FKBP_0hA
- GSM7789529 ATACseq_OCILY1_FOXO1_FKBP_0hB
- GSM7789530 ATACseq_OCILY1_FOXO1_FKBP_0.25hA
- GSM7789531 ATACseq_OCILY1_FOXO1_FKBP_0.25hB
- GSM7789532 ATACseq_OCILY1_FOXO1_FKBP_0.5hA
- GSM7789533 ATACseq_OCILY1_FOXO1_FKBP_0.5hB
- GSM7789534 ATACseq_OCILY1_FOXO1_FKBP_1hA
- GSM7789535 ATACseq_OCILY1_FOXO1_FKBP_1hB
- GSM7789536 ATACseq_OCILY1_FOXO1_FKBP_2hA
- GSM7789537 ATACseq_OCILY1_FOXO1_FKBP_2hB
- GSM7789538 ATACseq_SUDHL4_FOXO1_FKBP_0hA
- GSM7789539 ATACseq_SUDHL4_FOXO1_FKBP_0hB
- GSM7789540 ATACseq_SUDHL4_FOXO1_FKBP_0.5hA
- GSM7789541 ATACseq_SUDHL4_FOXO1_FKBP_0.5hB
- GSM7789542 ATACseq_SUDHL4_FOXO1_FKBP_1hA
- GSM7789543 ATACseq_SUDHL4_FOXO1_FKBP_1hB
- GSM7789544 ATACseq_SUDHL4_FOXO1_FKBP_2hA
- GSM7789545 ATACseq_SUDHL4_FOXO1_FKBP_2hB
- GSM7789546 ATACseq_SUDHL4_FOXO1_FKBP_2hC
- GSE254715 Mutant FOXO1 Controls an Oncogenic Network via Enhancer Accessibility and RNA Polymerase Pause Release [CUT&RUN] 6 samples same disease briefing · shares foxo1, accessibility, polymerase, oncogenic, controls, enhancer, network
- GSE139022 KDM4A/KDM4C lysine demethylases sustain an oncogenic transcriptional program in diffuse large B-cell lymphoma [ChIP-Seq] 31 samples same disease briefing · shares oncogenic
- GSE230396 Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma 132 samples same disease briefing · shares enhancer
- GSE139185 KDM4A/KDM4C lysine demethylases sustain an oncogenic transcriptional program in diffuse large B-cell lymphoma 40 samples same disease briefing · shares oncogenic
- GSE139183 KDM4A/KDM4C lysine demethylases sustain an oncogenic transcriptional program in diffuse large B-cell lymphoma [RNA-Seq] 9 samples same disease briefing · shares oncogenic
- GSE231623 Effect of DLBCL-associated NOTCH2 mutants on genomic RBP-J localization and H3K27 acetylation 7 samples same disease briefing
- GSE262641 Discovery of golcadomide (CC-99282) as a promising drug candidate for diffuse large B-cell lymphoma (DLBCL) 6 samples same disease briefing
- GSE232330 Targeting AURKA to induce synthetic lethality in CREBBP-deficient DLBCL via attenuation of MYC expression 3 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.